Repare Therapeutics (NASDAQ:RPTX) Trading Down 4%
Repare Therapeutics (NASDAQ:RPTX) Trading Down 4%
Shares of Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) fell 4% on Tuesday . The stock traded as low as $12.92 and last traded at $12.92. 987 shares traded hands during trading, a decline of 99% from the average session volume of 175,869 shares. The stock had previously closed at $13.46.
週二，雷帕雷治療公司(Repare Treateutics Inc.)的股價下跌了4%。該股一度跌至12.92美元，最後報12.92美元。987股股票在交易中成交，較175,869股的平均成交量下降了99%。該股此前收盤價為13.46美元。
Analyst Ratings Changes
分析師評級發生變化
A number of equities research analysts recently issued reports on RPTX shares. HC Wainwright lowered their price objective on Repare Therapeutics from $38.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, November 17th. Capital One Financial restated an "overweight" rating and set a $28.00 price target on shares of Repare Therapeutics in a research note on Friday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $30.80.
一些股票研究分析師最近發佈了關於RPTX股票的報告。11月17日，星期四，HC Wainwright在一份研究報告中將Repare治療公司的目標價從38.00美元下調至25.00美元，並對該股設定了“買入”評級。Capital One Financial在週五的一份研究報告中重申了“增持”評級，併為Repare治療公司的股票設定了28.00美元的目標價。一名研究分析師對該股的評級為持有，五名分析師對該公司股票的評級為買入。根據MarketBeat.com的數據，該公司目前的普遍評級為“適度買入”，平均目標價為30.80美元。
Repare Therapeutics Price Performance
修復治療藥物的價格表現
The business's 50-day moving average price is $15.50 and its 200 day moving average price is $13.94.
該業務的50日移動均線價格為15.50美元，200日移動均線價格為13.94美元。
Insider Buying and Selling
內幕買賣
In other Repare Therapeutics news, Director Davis Jerel sold 250,000 shares of the firm's stock in a transaction dated Friday, December 9th. The stock was sold at an average price of $16.00, for a total value of $4,000,000.00. Following the sale, the director now owns 2,094,451 shares of the company's stock, valued at approximately $33,511,216. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 30.30% of the stock is owned by company insiders.
在Repare Treateutics的其他新聞中，董事Davis Jerel在一筆日期為12月9日(星期五)的交易中出售了250,000股該公司股票。股票以16.00美元的平均價格出售，總價值為4,000,000.00美元。交易完成後，董事現在持有該公司2094,451股股票，價值約33,511,216美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過此超鏈接。30.30%的股份由公司內部人士持有。
Institutional Trading of Repare Therapeutics
Repare治療藥物的制度性交易
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Fred Alger Management LLC increased its stake in Repare Therapeutics by 6.8% in the third quarter. Fred Alger Management LLC now owns 24,311 shares of the company's stock valued at $295,000 after acquiring an additional 1,539 shares during the last quarter. State Street Corp raised its stake in shares of Repare Therapeutics by 1.2% during the third quarter. State Street Corp now owns 53,475 shares of the company's stock worth $649,000 after acquiring an additional 648 shares in the last quarter. Algert Global LLC purchased a new stake in shares of Repare Therapeutics in the 3rd quarter valued at $344,000. Trexquant Investment LP grew its holdings in shares of Repare Therapeutics by 55.5% during the 3rd quarter. Trexquant Investment LP now owns 79,674 shares of the company's stock valued at $966,000 after purchasing an additional 28,447 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Repare Therapeutics by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 73,842 shares of the company's stock worth $895,000 after purchasing an additional 600 shares during the period. Hedge funds and other institutional investors own 78.19% of the company's stock.
幾家機構投資者和對衝基金最近改變了他們在該股的頭寸。弗雷德·阿爾傑管理有限責任公司第三季度將其在Repare Treateutics的持股增加了6.8%。弗雷德·阿爾傑管理有限責任公司在上個季度增持了1,539股股票後，現在擁有24,311股該公司股票，價值29.5萬美元。道富集團在第三季度增持了Repare Treateutics的股份1.2%。道富銀行目前持有53,475股該公司股票，價值649,000美元，此前該公司在上個季度又收購了648股。阿爾蓋特全球有限責任公司在第三季度購買了Repare治療公司的新股份，價值344,000美元。Trexquant Investment LP在第三季度增持了Repare Treeutics的股票55.5%。Trexquant Investment LP現在擁有79,674股該公司的股票，價值966,000美元，在上個季度又購買了28,447股。最後，先鋒集團在第三季度將其在Repare治療公司的地位提高了0.8%。先鋒集團目前持有73,842股該公司股票，價值895,000美元，在此期間又購買了600股。對衝基金和其他機構投資者持有該公司78.19%的股份。
About Repare Therapeutics
關於Repare Treeutics
(Get Rating)
(獲取評級)
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
Repare治療公司是一家臨牀階段的精確腫瘤學公司，通過在加拿大和美國使用其合成致命性方法來發現和開發治療方法。該公司使用其SNIPRx，這是一個專有的、全基因組的和支持CRISPR的平臺，以系統地發現和開發專注於基因組不穩定性(包括DNA損傷修復)的高度針對性的癌症療法。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
- Can Lockheed Martin Corporation Hit Another All-Time High in Q1?
- Marathon Digital Holdings, Inc: Slow And Steady Wins The Race
- The WD-40 Company Is Ready To Rebound, But Will It?
- Skechers Not Nike Is The Sneaker Stock to Own for 2023
- Can The Rally In e.l.f. Beauty Stock Continue?
- 免費獲取StockNews.com關於Repare治療的研究報告(RPTX)
- 洛克希德·馬丁公司第一季度能否再創歷史新高？
- 馬拉鬆數字控股公司：穩紮穩打贏得比賽
- WD-40公司已經準備好反彈了，但它會嗎？
- 斯凱奇而不是耐克是2023年擁有的斯內克股票
- E.L.F.的拉力賽能否。美容股繼續？
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Repare治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Repare Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。